Can Novavax Beat Moderna and Pfizer in Preventing Severe COVID?
Preventing severe cases of coronavirus has been a major goal of vaccination campaigns. That's because these cases put individuals at a higher risk for hospitalization or even death. In this Motley Fool Live video recorded on June 22, healthcare and cannabis bureau editor and analyst Olivia Zitkus and Fool.com contributor Adria Cimino discuss the performance of Novavax's (NASDAQ: NVAX) vaccine candidate and how it compares to today's leaders Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE).
Source Fool.com
